Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 38 clinical trials
Study of TAK-672 in Participants With Acquired Hemophilia A

The main aims of the study are to learn if TAK-672 can control bleeds in participants with acquired hemophilia A and if the participants have side effects from TAK-672. Acquired hemophilia A is when people's immune system attacks specific proteins, known as clotting factors, in their bodies. This is different …

  • 0 views
  • 23 Mar, 2022
  • 9 locations
Enhancement of the Haemostatic Effect of Platelets in the Presence of High Normal Concentrations of Von Willebrand Factor (Will-Plate)

Assessment of high-normal dosage of Wilate ® compared to placebo administered in combination with platelets to assess reduction of amount of blood loss, need of transfusion products and outcome (length of stay, mortality) in patients with bleeding in comparison.

coagulation factor
prasugrel
hemostatic
ticagrelor
clopidogrel
  • 0 views
  • 06 May, 2022
  • 1 location
Genetic Background of Patients With Low Von Willebrand Factor Levels (LOVMIC)

Von Willebrand disease (VWD) is caused by either quantitative or qualitative von Willebrand (VWF) defects and is the commonest inherited bleeding disorder with an estimated prevalence of about 1% in the general population. According to several guidelines, patients with a mild quantitative reduction in VWF (30-50 IU/dL) should be labeled …

Accepts healthy volunteers
  • 0 views
  • 08 Mar, 2022
A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A

This study is for young children with severe hemophilia A who have previously not been treated with BAX855 or other FVIII concentrates. The main aim of the study is to check for side effects from treatment with BAX855. This includes the buildup of antibodies against FVIII which may stop BAX855 …

bax 855
hemostatic
severe haemophilia a
immune tolerance induction
antihemophilic factor
  • 0 views
  • 26 Jan, 2022
  • 90 locations
Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle".

In this study researchers want to gather more information about safety and effectiveness of BAY 2599023 (DTX201), a drug therapy that delivers the human factor VIII gene into the human body by

coagulation factor
bleeding tendency
severe haemophilia a
antihemophilic factor
  • 208 views
  • 13 May, 2022
  • 10 locations
A Gene Transfer Study for Hemophilia A

This clinical research study is being conducted by Spark Therapeutics, Inc. to determine the safety and efficacy of the factor VIII gene transfer treatment with SPK-8011 in individuals with

cryoprecipitate
antihemophilic factor
  • 842 views
  • 26 Mar, 2022
  • 14 locations
A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors

used for prevention of bleeding episodes. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). When and how often participants will receive Mim8 is dependent on

  • 0 views
  • 12 Apr, 2022
  • 30 locations
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors (HAVEN 7)

age with severe hemophilia A (intrinsic factor VIII [FVIII] level <1%) without FVIII inhibitors. The study is designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of

  • 0 views
  • 29 Apr, 2022
  • 20 locations
Six Month lead-in Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)

To establish a minimum of 6 months of prospective efficacy data of current FIX prophylaxis replacement therapy in the usual care setting of hemophilia B subjects, who are negative for nAb to AAV-Spark100, prior to the Phase 3 gene therapy study. To establish a minimum of 6 months of prospective …

christmas disease
Factor VIII
gene therapy
antihemophilic factor
hemophilia
  • 238 views
  • 05 May, 2022
  • 43 locations
Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A

introduce or deliver a gene that creates and stores a protein Factor VIII (FVIII) in your platelets. These platelets are made from stem cells (mother cells for your bone marrow) that are removed from your

coagulation factor
renal function
total bilirubin
antihemophilic factor
cirrhosis
  • 10 views
  • 31 Oct, 2021
  • 1 location